Highlights Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Real-time Estimate Cboe BZX Other stock markets 01:28:20 10/05/2024 am IST			5-day change	1st Jan Change
0.515 ^USD	+2.51%		-0.02%	-3.94%

22/03	Sangamo Therapeutics Prices $24 Million Registered Direct Offering	MT
14/03	Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sangamo Therapeutics Prices $24 Million Registered Direct Offering	22/03	MT
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps	13/03	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920	05/02	CI
Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial	13/12	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11	CI
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy	24/23/24	CI
Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q2 Revenue $6.8M, vs. Street Est of $15.3M	09/23/09	MT
Sangamo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Sangamo Therapeutics to Develop Zinc Finger Proteins for Epigenetic Editing With Chroma Medicine	20/23/20	MT
Sangamo Therapeutics, Inc. and Chroma Medicine, Inc. Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing	20/23/20	CI
Sangamo Therapeutics, Eli Lilly Unit Sign Research Deal to Evaluate Adeno-Associated Virus Capsids	17/23/17	MT
Sangamo Therapeutics, Inc. Announces Research Evaluation and Option Agreement with Prevail for Novel Engineered Capsids	17/23/17	CI
US FDA approves BioMarin's gene therapy for hemophilia A	30/23/30	RE
Sangamo Therapeutics, Inc. and Voyager Therapeutics, Inc. Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease	29/23/29	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
North American Morning Briefing : Meta Gives Boost to Nasdaq; GDP Report Up Ahead	27/23/27	DJ
Sangamo Therapeutics, Inc. Provides Earnings Guidance for the First Quarter Ended March 31, 2023	27/23/27	CI
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group	13/23/13	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Highlights

Filters